Vincent Rajkumar, Professor of Medicine at the Mayo Clinic in Rochester, shared a post on X:

“At ECOG-ACRIN Cancer Research Group meeting today, I recollected one of the most consequential clinical trials in myeloma.

15 years ago we demonstrated that we can save a lot of lives by just reducing dexamethasone dose.”

Title: Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial.

Authors: Vincent Rajkumar, Susanna Jacobus, Natalie S Callander, Rafael Fonseca, David H Vesole, Michael E Williams, Rafat Abonour, David S Siegel, Michael Katz, Philip R Greipp

You can read the Full Article on The Lancet Oncology

Vincent Rajkumar: 15 Years Since We Changed Myeloma Care with Less Dexamethasone